ArticleHaematologica2025

Lower-intensity chemo-immunotherapy with cladribine, low-dose cytarabine, venetoclax and blinatumomab produces high response rates in patients with

Roberta S Azevedo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.